PATENT CLAIM ANALYSIS

Application Number: 15910525
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["424", "186100"]

Abstract:
Modified viruses and methods for preparing the modified viruses are provided. Vaccines that contain the viruses are provided. The viruses can be used in methods of treatment of diseases, such as proliferative and inflammatory disorders, including cancer, and as anti-tumor and/or antiangiogenic agents. The viruses also can be used in diagnostic methods.

Claim (Index 17):
The method of  claim 1 , wherein:\n the recombinant vaccinia virus comprises an inactivated hemagglutinin (HA) gene, thymidine kinase (TK) gene, and F14.5L gene or locus, wherein nucleic acid encoding the diagnostic or therapeutic protein is inserted into one or more gene locus selected from among the HA gene locus, the TK gene locus and the F14.5L gene locus in the vaccinia virus.

Metadata:
- Claim Count in Document: 41.0
- Percentile: 90.0
- Lexical Diversity: 1.63889
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['14638604', '13136519', '11975090', '12080766', '12660314']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.726542234494799
- 35 USC 102 Novelty (BERT): 0.6255324182152173
- Combined Prediction Score: 0.7164412528668409
- Mean Citation Score: 511.316062
- Max Citation Score: 563.9477
- Similarity Product: 534.1066556810678

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test